6:44 am Novartis AG announced Lucentis approval in fourth Japanese indication, diabetic macular edema; Pivotal clinical data in Asian patients show a significant increase in mean visual acuity following treatment with Lucentis compared with
View todays social media effects on NVS
View the latest stocks trending across Twitter. Click to view dashboard
See who Novartis is hiring next, click here to view
